Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
| Conditionnement | Référence | Disponibilité | Prix |
|---|---|---|---|
| 25 g | Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit. | 172,00 $ |
A propos de cet article
Formule empirique (notation de Hill) :
C9H19N3O6
Numéro CAS:
Poids moléculaire :
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
172,00 $
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
L-Ornithine L-aspartate salt, powder
assay
≥98% (TLC)
Quality Level
form
powder
color
white to off-white
storage temp.
2-8°C
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
Biochem/physiol Actions
L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.
Other Notes
Product of arginine degradation by arginase
1 of 1
Cet article | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (TLC) | assay ≥99% | assay ≥99% | assay ≥99.0% (AT) |
| storage temp. 2-8°C | storage temp. - | storage temp. - | storage temp. - |
| color white to off-white | color white | color white | color - |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 100 |
Classe de stockage
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| O7125-25G | 04061834248392 |
| O7125-100G | 04061834248385 |


